- Home
- MTVA vs CLRB Comparison
MTVA vs CLRB Comparison
Compare MTVA & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- CLRB
- Stock Information
- Founded
- MTVA 2014
- CLRB 2002
- Country
- MTVA United States
- CLRB United States
- Employees
- MTVA N/A
- CLRB N/A
- Industry
- MTVA
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- MTVA
- CLRB Health Care
- Exchange
- MTVA NYSE
- CLRB Nasdaq
- Market Cap
- MTVA 16.8M
- CLRB 15.3M
- IPO Year
- MTVA N/A
- CLRB N/A
- Fundamental
- Price
- MTVA $1.60
- CLRB $0.31
- Analyst Decision
- MTVA Strong Buy
- CLRB Buy
- Analyst Count
- MTVA 1
- CLRB 2
- Target Price
- MTVA $12.00
- CLRB $28.00
- AVG Volume (30 Days)
- MTVA 23.0K
- CLRB 1.4M
- Earning Date
- MTVA 03-27-2025
- CLRB 03-26-2025
- Dividend Yield
- MTVA N/A
- CLRB N/A
- EPS Growth
- MTVA N/A
- CLRB N/A
- EPS
- MTVA N/A
- CLRB N/A
- Revenue
- MTVA N/A
- CLRB N/A
- Revenue This Year
- MTVA N/A
- CLRB N/A
- Revenue Next Year
- MTVA N/A
- CLRB N/A
- P/E Ratio
- MTVA N/A
- CLRB N/A
- Revenue Growth
- MTVA N/A
- CLRB N/A
- 52 Week Low
- MTVA $1.51
- CLRB $0.22
- 52 Week High
- MTVA $6.75
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- CLRB 46.10
- Support Level
- MTVA N/A
- CLRB $0.26
- Resistance Level
- MTVA N/A
- CLRB $0.35
- Average True Range (ATR)
- MTVA 0.00
- CLRB 0.03
- MACD
- MTVA 0.00
- CLRB 0.02
- Stochastic Oscillator
- MTVA 0.00
- CLRB 61.40
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.